QUERCIS

ABOUT

TEAM

SCIENCE

HIGHLIGHTS

PUBLICATIONS

EXPANDED ACCESS

NEWS

CONTACT

QUERCIS

2026 Galien Award Nominee

Heal the world

™

Transforming Global Health with Science & Compassion

At Quercis Pharma, we are redefining what is possible in human health. Our investigational therapies target some of the world’s most urgent medical challenges with the goal of bringing safe, effective, and affordable medicines to patients everywhere.

QUERCIS AT A GLANCE

Kinisoquin™ acts on 13+ biomarkers. Highlights from Phase 2:

Phase 3

Lead program under FDA Special Protocol Assessment

Zero

Zero VTE and no major bleeding in Phase 2

−73%*

PDI (protein disulfide isomerase)

−22%*

D-Dimer

−58%*

sP-selectin

2045

Patent protection runway

*Statistically significant reduction in Phase 2

Harvard Medical School · Beth Israel Deaconess · National Institutes of Health · Memorial Sloan Kettering · ETH Zürich · Pasteur Institute

PIPELINE

A Phase 3 lead program, with a platform behind it

Oncology

VTE in Metastatic Pancreatic Cancer

Kinisoquin™ monotherapy · FDA Special Protocol Assessment

Phase 3

VTE in Ovarian Cancer

Kinisoquin™ monotherapy · with NIH and MSKCC

Phase 2/3

Cancer (All Solid Tumors) — RTT (Right to Try) and Expanded Access (EA)

Kinisoquin™ + Zafirlukast combination

Phase 2/3

Lung Cancer

Kinisoquin™ + Zafirlukast combination

Phase 2

Hematology / Thrombosis

Sickle Cell Disease

Kinisoquin™ monotherapy · steady state, crisis and transfusion dependent

Phase 3

Virally Induced Thrombosis

Kinisoquin™ monotherapy · incl. SARS-CoV-2 and Ebola

Planned

Virology

Measles, SARS-CoV-2, H1N1, H5N1 and Ebola

Kinisoquin™ + Zafirlukast combination

Phase 2/3

Explore the science

Company highlights

TEAM

A world-class team for a global mission

Senior Leadership

Our leadership team has guided the approval of more than 50 therapies, supported by a Scientific Advisory Board of world-class scientists and clinicians

Thomas Lines D.Sc (h.c.)

Chairman and CEO

Nishant Pandey

COO & Deputy CEO

Stefan Wohlfeil, MD

CMO

Andreas Schuh

CFO

Richard O'Neil JD

COO, Quercis USA

Daniel Drexler, MD

CEO, Quercis USA

Board of Directors

Thomas Lines D.Sc (h.c.)

Chairman and CEO

Gerhard Ries, Ph.D

Board Member

Scientific Advisory Board

Our Scientific Advisory Board brings together global leaders in oncology, hematology, immunology and neurology, whose members have overseen the registration of 17 cancer drugs and published more than 500 papers across Harvard, Cornell, ETH Zürich and the Pasteur Institute

Prof. Dr. Jean-Pierre Kinet

Immunologist and Professor Emeritus at Harvard Medical School

Prof. Dr. Jean Pierre Bizzari

Chairman Scientific Advisory Board, Chairman of EORTC New Drug Advisory Committee, Former CMO Celgene

Prof. Dr. Manuel Hildalgo

Chief of the Division of Hematology and Medical Oncology at the Weill Department of Medicine, Cornell University

Prof. Dr. Louis Barbeito

Former Head Laboratory of Neurodegeneration at Pasteur Institute in Uruguay

Prof. Dr. Simone Schürle-Finke

Head of Responsive Biomedical System Lab at ETH, Zurich

VIEW FULL TEAM

TEAM

A world-class team for a global mission

Senior Leadership

Our leadership team has guided the approval of more than 50 therapies, supported by a Scientific Advisory Board of world-class scientists and clinicians

Thomas Lines D.Sc (h.c.)

Chairman and CEO

Nishant Pandey

COO & Deputy CEO

Stefan Wohlfeil, MD

CMO

Andreas Schuh

CFO

Richard O'Neil JD

COO, Quercis USA

Daniel Drexler, MD

CEO, Quercis USA

Board of Directors

Thomas Lines D.Sc (h.c.)

Chairman and CEO

Gerhard Ries, Ph.D

Board Member

Scientific Advisory Board

Prof. Dr. Jean-Pierre Kinet

Immunologist and Professor Emeritus at Harvard Medical School

Prof. Dr. Jean Pierre Bizzari

Chairman Scientific Advisory Board, Chairman of EORTC New Drug Advisory Committee, Former CMO Celgene

Prof. Dr. Manuel Hildalgo

Chief of the Division of Hematology and Medical Oncology at the Weill Department of Medicine, Cornell University

Prof. Dr. Louis Barbeito

Former Head Laboratory of Neurodegeneration at Pasteur Institute in Uruguay

Prof. Dr. Simone Schürle-Finke

Head of Responsive Biomedical System Lab at ETH, Zurich

VIEW FULL TEAM

TEAM

A world-class team for a global mission

Senior Leadership

Our leadership team has guided the approval of more than 50 therapies, supported by a Scientific Advisory Board of world-class scientists and clinicians

Thomas Lines D.Sc (h.c.)

Chairman and CEO

Nishant Pandey

COO & Deputy CEO

Stefan Wohlfeil, MD

CMO

Andreas Schuh

CFO

Richard O'Neil JD

COO, Quercis USA

Daniel Drexler, MD

CEO, Quercis USA

Board of Directors

Thomas Lines D.Sc (h.c.)

Chairman and CEO

Gerhard Ries, Ph.D

Board Member

Scientific Advisory Board

Prof. Dr. Jean-Pierre Kinet

Immunologist and Professor Emeritus at Harvard Medical School

Prof. Dr. Jean Pierre Bizzari

Chairman Scientific Advisory Board, Chairman of EORTC New Drug Advisory Committee, Former CMO Celgene

Prof. Dr. Manuel Hildalgo

Chief of the Division of Hematology and Medical Oncology at the Weill Department of Medicine, Cornell University

Prof. Dr. Louis Barbeito

Former Head Laboratory of Neurodegeneration at Pasteur Institute in Uruguay

Prof. Dr. Simone Schürle-Finke

Head of Responsive Biomedical System Lab at ETH, Zurich

VIEW FULL TEAM

OUR PARTNERS

Quercis partners with leading academic institutions, regulators, patient organizations, and industry leaders to accelerate the development of accessible medicines worldwide.